ACADL and neoplasm: Since only a small portion (19.23%) of advanced disease tissues overexpressed LCAD, whether such patients have different cellular control of the tumor proliferation rate, or sensitivity to chemotherapy or irradiation, needs to be investigated with larger clinical samples.